New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer

“The nature of the body is the beginning of medical science”-Hippocrates. From the chosen Dhanvantri of ancient India to Imhotep of Egypt, to Huangdi of China, the disease was seen as a combination of the supernatural and the natural and medicine focused on healing the soul and the body. While prac...

Full description

Bibliographic Details
Published in:	Journal of Rawalpindi Medical College
Main Author:	Zein El Amir
Format:	Article
Language:	English
Published:	Rawalpindi Medical University 2023-06-01
Online Access:	https://www.journalrmc.com/index.php/JRMC/article/view/2330

Similar Items

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy
by: Pedro Henrique Isaacsson Velho, et al.
Published: (2018-04-01)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
by: Vincenza Conteduca, et al.
Published: (2021-01-01)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
by: Matthew E. Pollard, et al.
Published: (2017-01-01)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
by: Gul A, et al.
Published: (2019-08-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer
by: Kullmann Tamás, et al.
Published: (2022-04-01)

Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer
by: Julia Belone Lopes, et al.
Published: (2025-08-01)

Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
by: Sandra Doveson, et al.
Published: (2025-03-01)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
by: Joelle El-Amm, et al.
Published: (2013-01-01)

Research progress on the transition metchansim of metastatic hormone-sensitive prostate cancer to metastatic castration-resistant prostate cancer
by: MAO Yun, et al.
Published: (2025-02-01)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
by: Giuseppe Fallara, et al.
Published: (2023-06-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance
by: İvo Gökmen, et al.
Published: (2024-12-01)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Vipin Lohiya, et al.
Published: (2016-10-01)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
by: Kevin K. Zarrabi, et al.
Published: (2023-06-01)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019-03-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Current status of radionuclide therapies in metastatic castration-resistant prostate cancer
by: Xin Fei, et al.
Published: (2025-09-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
by: Sree M. Lanka, et al.
Published: (2023-04-01)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
by: Koji Hatano, et al.
Published: (2023-10-01)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01)

Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer
by: Fred Saad
Published: (2013-08-01)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
by: Mukherji D, et al.
Published: (2014-05-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer
by: Gabrielle Robin, et al.
Published: (2024-08-01)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
by: Simon Rauch, et al.
Published: (2016-06-01)

Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Neal Shore, et al.
Published: (2024-10-01)

An experience with abiraterone as treatment for metastatic castration-resistant prostate cancer: Changhua christian hospital experience
by: Wan-yun Fang, et al.
Published: (2016-06-01)

Influence of treatment with abiraterone and enzalutamide on development of sarcopenia in patients with metastatic castration resistant prostate cancer
by: S. Fischer, et al.
Published: (2020-07-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Optimal treatment for castration-resistant prostate cancer
by: Kouji Izumi, et al.
Published: (2014-06-01)

Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
by: Meagher MF, et al.
Published: (2023-11-01)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
by: Marina N. Sharifi, et al.
Published: (2025-08-01)